|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.07 USD | +2.14% |
|
+6.14% | +20.22% |
Business description: Monte Rosa Therapeutics, Inc.
Number of employees: 187
Sales by Activity: Monte Rosa Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology (Startups) | - | - | - | 75.62M | 124M |
Geographical breakdown of sales: Monte Rosa Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | - | - | - | 75.62M | 124M |
Executive Committee: Monte Rosa Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Markus Warmuth
CEO | Chief Executive Officer | 55 | 01/01/2020 |
Magnus Walter
CTO | Chief Tech/Sci/R&D Officer | - | 17/03/2026 |
| Chief Operating Officer | 54 | 01/03/2021 | |
John Castle
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
Filip Janku
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/06/2021 |
Composition of the Board of Directors: Monte Rosa Therapeutics, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Markus Warmuth
BRD | Director/Board Member | 55 | 01/01/2020 |
Ali Behbahani
BRD | Director/Board Member | 49 | 01/04/2020 |
| Director/Board Member | 57 | 01/06/2020 | |
Christine Siu
BRD | Director/Board Member | 49 | 01/12/2020 |
Chandra Paul Leo
BRD | Director/Board Member | 55 | 01/09/2020 |
Andrew Schiff
CHM | Chairman | 60 | 01/06/2023 |
Jan Skvarka
CHM | Chairman | 59 | 01/03/2022 |
Anthony Manning
BRD | Director/Board Member | 64 | 25/07/2023 |
Eric Hughes
BRD | Director/Board Member | 56 | 13/12/2024 |
Company details: Monte Rosa Therapeutics, Inc.
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.14% | +6.14% | +306.25% | +177.21% | 1.58B | |
| +3.54% | +4.21% | -8.16% | -2.76% | 43.24B | |
| +0.59% | +6.62% | +316.93% | +554.15% | 35.25B | |
| +0.87% | +3.27% | +5.84% | +52.02% | 30.22B | |
| +1.20% | -5.26% | +9.40% | -20.70% | 28.01B | |
| -1.06% | -3.71% | +9.08% | +19.56% | 24.08B | |
| +0.89% | -0.82% | - | - | 14.16B | |
| +0.92% | +0.05% | +49.64% | +106.75% | 13.01B | |
| +2.80% | +4.05% | +9.64% | +15.34% | 12.7B | |
| +0.19% | +4.28% | +102.34% | +92.28% | 12.54B | |
| Average | +1.23% | +0.06% | +88.99% | +110.43% | 21.48B | |
| Weighted average by Cap. | +1.29% | -0.18% | +69.84% | +119.12% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLUE Stock
- Company Monte Rosa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
